Gene therapy aimed at treating idiopathic Parkinson's Disease
Official title: Gene Therapy for Idiopathic Parkinson's Disease
Funded at Mark Therapeutics, INC. · NIH-10919327 · Data updated 2026-11-12
This study is testing a new gene therapy for people with idiopathic Parkinson's Disease, which is a common form of the condition that doesn't run in families, to see if it can help improve brain function and slow down symptoms.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mark Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $494,040 |
| NIH project number | 1R43NS134446-01A1 |
| Project ID | NIH-10919327 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic Parkinson's Disease who do not have genetic mutations or a family history of the condition.
✕Less likely to help
Patients with Parkinson's Disease caused by known genetic mutations or those with a strong family history of the disease may not benefit from this research.
What this research studies
This research focuses on developing a novel gene therapy specifically for patients with idiopathic Parkinson's Disease (idPD), which affects around 80% of Parkinson's patients who do not have genetic mutations or a family history of the disease. The approach involves using an Adeno-Associated Viral (AAV) vector to deliver a functional protein that can restore critical cellular functions in dopamine-producing neurons, potentially halting disease progression. The therapy has shown promising results in preclinical models, demonstrating safety and efficacy in slowing motor dysfunction. The research aims to optimize and validate this therapy through rigorous preclinical studies.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option that modifies the progression of idiopathic Parkinson's Disease.
How similar studies have gone: This approach is novel and has shown initial success in preclinical models, but further validation in human trials is needed.
Where this research is happening
-
Mark Therapeutics, INC.
San Diego, United States Active
Researchers
- Principal investigator: Bolotina, Victoria M — Mark Therapeutics, INC.
- Study coordinator: Bolotina, Victoria M
Related research
Other NIH-funded projects on the same topics.
-
Gut-brain clues in Parkinson’s disease: supplement to a large registry
A plant-wide supplement to an NIH program will enroll people with Parkinson’s, with and without GI symptoms, plus healthy controls, to study how gut function, brain signals, and sleep rhythms relate to Parkinson’s symptoms.
-
Gut-brain connections in Parkinson’s disease: how the gut and environment shape symptoms
A Mayo Clinic team is studying how gut problems, environmental factors, and genetics together influence Parkinson’s disease and its GI symptoms to find biomarkers and better understanding of the disease.
-
Gut-brain communication in Parkinson’s disease for better symptoms and daily life
This project enrolls people with Parkinson’s disease and healthy controls to build a big registry and study how gut function, brain signals, sleep, and circadian rhythms relate to PD symptoms.
-
Gut microbiome and Parkinson's disease: how gut bugs relate to symptoms and progression
A multi-year study will look at gut bacteria and related markers in people with Parkinson’s disease to understand how the gut-brain connection may influence symptoms and progression.
-
Gut-Brain Axis in Parkinson’s Disease: biomarkers and procedures to track progression
A patient-focused program to study how gut health and the brain interact in Parkinson’s disease using biomarkers and clinical procedures.
-
Understanding posture and movement in Parkinson’s patients to reduce falls
A study using wearable sensors to track real-world balance and movement in people with Parkinson’s disease to help prevent falls.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.